Brazil: The Europa Case & Other Trademark Developments in Brazil

Co-written by Deborah Portilho

The Europa Case

The amount of damages that are awarded by Brazilian courts for trademark infringement have normally been insignificant. One particular case has become an exception. The case involves use of the mark EUROPA by Fiat Automóveis S.A. (Fiat) from 1979 to 1981 to identify a line of cars. Mecânica Europa S.A. (Mecânica), which has held a registration on EUROPA since July 1976 for automobile parts, sued Fiat for trademark infringement in 1982, after having notified the company requesting that Fiat cease use of the mark or pay royalties of 3%. Mecânica was unsuccessful at first instance as the court accepted Fiat’s argument that it had not used EUROPA as a mark, but merely in a descriptive sense, notwithstanding that the word appeared on all advertising material and even on Fiat’s manual.

Mecânica appealed the decision insisting on damages equivalent to 3%. The appeal was sustained but the Court awarded damages of 1.5% of the value of the cars sold (during the three year period) by Fiat bearing the mark EUROPA. It was Fiat’s turn to appeal, but without success, and the decision was upheld, with Fiat being ordered to pay R$3.792.378,00 (around US$1,600,000.00) plus legal costs. Fiat then filed an appeal to the Superior Court of Justice on grounds of legal procedure, rather than the legal or factual basis for the decision. This appeal was dismissed in November 2001, with the Court deciding that there had been no violation of the Code of Civil Procedure, as Fiat had claimed. Fiat’s attorneys indicated in a written note shortly thereafter that all possible steps would be taken until the decision was overturned. However, the only possible appeal now would be to the Supreme Court, which would only hear the case if it could be alleged that Fiat’s constitutional rights had been violated. As such, Fiat may have little alternative but to pay the damages, which, after adjustments for inflation, now stand at R$8.500.000,00 which is around US$3,500,000.00.


While the introduction of the Eighth Edition of the Nice Classification may increase the costs of protecting a mark, depending on the services covered, discussions are now taking place in Brazil to encourage the country to join the Madrid Protocol promising to introduce major cost savings. It is known that under this system, administered by the World Intellectual Property Organization, a single registration gives protection in various jurisdictions. However, many important countries, particularly in the Americas, are not yet signatories of the Agreement, including, United States, Canada, Mexico, Argentina and Brazil.

The Madrid Protocol has introduced a number of changes to the Madrid Agreement which have made it more attractive to these countries, which are now expected to join. One of the major changes is that the basis for an international registration may now be an application rather than a registration. If this basic application is rejected in its country of filing within five years, or due to an action which was commenced within the five year period, then all the applications on which it was based die with it. This is known as the principal of central attack. However, what has become known as the "Dutch proposal" has softened this blow as the applicant may now apply in each individual country named in the refused international application, claiming the priority date of the basic application.

The time limit in which national PTO’s must advise the applicant of refusal may be extended from 12 months, as fixed by the Madrid Agreement, to 18 months, if the contracting country so requests. However, even the extended period of 18 months may not be sufficient for the Brazilian PTO, which is currently taking in excess of two years to advise applicants that an opposition has been filed, or that an application has been rejected ex officio, and over four years to advise of rejection where there has been a third party opposition.

Along with the United States and many other countries in the Americas, Brazil is currently considering signing the Madrid Protocol. However, even if it were considered in Brazil’s interests to join, the practicalities of the system would require significant restructuring of the Brazilian PTO, which would struggle to meet its obligations under the Madrid Protocol, particularly with regard to the 18 month period to inform of rejection. There would also have to be a major recruitment of

translators to deal with the immense volume of documents which would have to be translated from Portuguese into English or French, and vice versa.


The Eighth Edition of the Nice Classification was adopted by Brazil, along with the other signatories of the Nice Agreement, on January 1, 2002. The main change over the Seventh Edition is that Class 42, which is comprised of miscellaneous services, was divided into four distinct classes, as set out below:

Seventh Edition:

Class 42: Providing of food and drink; temporary accommodation; medical, hygienic and beauty care; veterinary and agricultural services; legal services; scientific and industrial research; computer programming; services that cannot be placed in other classes.

Eighth Edition:

Class 42: Scientific and technological services, including hardware and software development and legal services.

Class 43: Services for providing food and drink, and temporary accommodation.

Class 44: Medical services, for animals and humans including hygiene and beauty, and agriculture related services.

Class 45: Personal and social services rendered by other to meets the needs of individuals, and security services.

Applications filed as of January 1, 2002 must conform to the new classes, while applications filed before that date must be migrated to the new classes when the final issuance fees are paid, in applicable cases. Registrations will only be migrated to the new classes on renewal, which is every ten years.


On February 27, 2002, ANVISA, the Brazilian National Agency of Sanitary Control, issued an official communication to pharmaceutical laboratories and importers in Brazil advising that, based on Article 5 of Decree 79,094/77, as of April 8, 2002, it would no longer permit the importation and sale of immunobiologicals (which, in principle, include vaccines and immunoglobulins) identified by trademarks. According to the official communication, in order to obtain the necessary import licenses, the packagings, labels and directions for use that come with these products ("bulas") must use the generic name of the substances.

This long-standing requirement was originally introduced by Article 5 of Law No. 6,360, of September 23, 1976, and later implemented by Article 5 of the cited Decree 79,094, of January 5, 1977, according to which "pharmaceutical products which contain only one active ingredient, immunotherapeutic products, drugs and pharmaceutical raw materials will not be allowed to be identified by commercial names."

Thereafter, Law 6,480, of December 1, 1977, altered certain aspects of Law 6,360 by including, inter alia, a fourth paragraph in its Article 5, which provided that "... pharmaceutical products which contain only one widely known active ingredient, at the Ministry of Health's discretion, and immunotherapeutic products, drugs and pharmaceutical raw materials must be identified by the respective denominations which appear in the Brazilian Pharmacopoeia, and must not bear, under any circumstance whatsoever, a commercial name or trademark".

These legal provisions were also recently addressed in ANVISA's Resolution - RDC No. 92, of October 23, 2000, which deals essentially with generic products and which reaffirmed, in the fourth paragraph of its Article 4, that "immunotherapeutic products cannot, under any circumstance, have coined names or trademarks, as per Article 5, § 4,of Law No. 6,360, of September 23, 1976, altered by Law No. 6,480, of December 1, 1977".

Notwithstanding the fact that these legal provisions have been in effect for more than twenty-five years, they apparently have never been enforced by the Ministry of Health (MOH), since vaccines and other immunotherapeutic products have been extensively commercialized in Brazil under their respective trademarks throughout this period.

Furthermore, the Brazilian Patent and Trademark Office (PTO) has consistently granted trademark registrations for immunotherapeutic products, with no restrictions whatsoever. This is not only logical, but is also in conformity with Article 7 of the Paris Convention, which provides that "the nature of the product on which the trademark will be used shall, in no case, constitute a bar to registration". Moreover, exactly the same provisions were adopted by the TRIPS Agreement in Article 15, Section 2, relating to trademarks.

It should also be observed that the Brazilian Industrial Property Law (No. 9,279), of May 14, 1996, assures to the owners of validly issued registrations the exclusive use of the respective trademarks throughout the Brazilian territory.

Furthermore, use of a registered trademark in Brazil, as in most countries, is not discretionary, but rather compulsory. In fact, according to Article 143, of our IP Law, if use of a mark is not initiated within 5 years from the date of grant of the respective registration, or if such use has been interrupted for more than 5 consecutive years, the corresponding registration shall be cancelled at the request of any party with a legitimate interest.

Considering all the above and that Brazil is signatory to both the Paris Convention and the TRIPS Agreement, and considering further that Article 2 of the latter treaty states that Members shall comply with the provisions of Articles 1 to 12 and 19 of the Paris Convention (Stockholm Revision), there seems to be no doubt that the provisions which prohibit the use of trademarks for immunotherapeutic products are of no effect.

Accordingly, although ANVISA's communication is supported by a legal provision originally introduced in 1976, the implementation of more recent and comprehensive legislation, such as the Paris Convention, TRIPS and the Brazilian Industrial Property Law, should be sufficient to impede ANVISA from effectively implementing the regulations under discussion. Moreover, there seems to be no logical reason behind this legal norm that could justify its implementation, either at present or in 1976 when Law 6,360 was introduced.

Based on the above legal aspects, the Brazilian Pharmaceutical Industries Union – SINDUSFARMA -, filed an administrative appeal to ANVISA and, as a result, the effects of the official communication at issue have been suspended until ANVISA rules on the appeal.

In addition to the legal questions, SINDUSFARMA and the Brazilian Society of Immunization, which are the entities currently directly involved with this subject, are also discussing with ANVISA other practical and technical issues concerning this matter.

If the administrative actions currently underway are not sufficient to persuade ANVISA to revoke this official requirement and, in this case, if the legal norm is actually applied, then the company(ies) suffering from the effects of the prohibitions will have to question the matter in court, on a case-by-case basis, or collectively. In the latter circumstance, the action would have to be instituted through an association, such as SINDUSFARMA or ABIFARMA (Brazilian Association of Pharmaceutical Industries), which in June 2002 will be converted into a federation under the name of FEBRAFARMA.


The surprising decision rendered by the Brazilian Superior Court of Justice on the EUROPA case and the adoption of the Nice Classification of Goods and Services by the Brazilian PTO could be an indication that Brazil is effecting positive changes to improve the trademark system not only by restraining trademark piracy through heavy penalties, which has been unusual in the past, but also by streamlining administrative proceedings within the PTO. However, there is general concern amongst practitioners that the PTO is encouraging the Government to take steps to join the Madrid Protocol when it is a known fact that serious delays in the prosecution of trademark applications make this unrealistic. Also on a negative note is the interference of Brazil’s health authorities in matters relating to intellectual property.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions